AstraZeneca PLC (LON: 0A4J)

London flag London · Delayed Price · Currency is GBP · Price in USD
68.15
-0.06 (-0.09%)
At close: Jan 22, 2025
2.14%
Market Cap 171.37B
Revenue (ttm) 38.20B
Net Income (ttm) 4.85B
Shares Out n/a
EPS (ttm) 3.10
PE Ratio 35.36
Forward PE n/a
Dividend 1.15 (1.72%)
Ex-Dividend Date Aug 9, 2024
Volume 27,760
Average Volume 8,597
Open 67.94
Previous Close 68.21
Day's Range 67.68 - 68.24
52-Week Range 60.48 - 87.62
Beta 0.18
RSI 59.41
Earnings Date Feb 6, 2025

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus... [Read more]

Industry Pharmaceutical Preparations
Founded 1992
Employees 89,900
Stock Exchange London Stock Exchange
Ticker Symbol 0A4J
Full Company Profile

Financial Performance

In 2023, AstraZeneca's revenue was $45.81 billion, an increase of 3.29% compared to the previous year's $44.35 billion. Earnings were $5.96 billion, an increase of 81.11%.

Financial numbers in USD Financial Statements

News

There is no news available yet.